Sei Investments Co. Acquires 35,459 Shares of Viridian Therapeutics, Inc. $VRDN

Posted by Brian Himes on Aug 12th, 2026

Sei Investments Co. lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 117.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 65,777 shares of the company’s stock after acquiring an additional 35,459 shares during the quarter. Sei Investments Co.’s holdings in Viridian Therapeutics were worth $1,287,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MetLife Investment Management LLC increased its holdings in Viridian Therapeutics by 0.8% during the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock valued at $1,369,000 after buying an additional 356 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Viridian Therapeutics by 0.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after acquiring an additional 380 shares during the period. US Bancorp DE raised its position in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after acquiring an additional 463 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Viridian Therapeutics by 0.3% during the 1st quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after purchasing an additional 659 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares during the last quarter.

Viridian Therapeutics Trading Down 0.4%

Shares of NASDAQ:VRDN opened at $22.97 on Wednesday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -6.82 and a beta of 0.91. The business has a 50-day moving average price of $18.65 and a 200-day moving average price of $21.45.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.09 EPS for the current year.

Analyst Ratings Changes

VRDN has been the subject of a number of recent research reports. Stifel Nicolaus set a $39.00 target price on shares of Viridian Therapeutics in a report on Wednesday, May 13th. The Goldman Sachs Group restated a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Truist Financial increased their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Viridian Therapeutics in a research note on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $38.93.

Get Our Latest Stock Report on VRDN

Viridian Therapeutics Company Profile

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.